Skip to main navigation Skip to search Skip to main content

LSD1: biologic roles and therapeutic targeting

Research output: Contribution to journal › Article › peer-review

Abstract

LSD1 (KDM1A; BHC110; AOF2) was the first protein reported to exhibit histone demethylase activity and has since been shown to have multiple essential roles in mammalian biology. Given its enzymatic activity and its high-level expression in many human malignancies, a significant recent focus has been the development of pharmacologic inhibitors. Here we summarize structural and biochemical knowledge of this important epigenetic regulator, with a particular emphasis on the functional and preclinical studies in oncology that have provided justification for the evaluation of tranylcypromine derivative LSD1 inhibitors in early phase clinical trials.

Original languageEnglish
Pages (from-to)1103-16
Number of pages14
JournalEpigenomics
Volume8
Issue number8
DOIs
Publication statusPublished - Aug 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Journal Article

Research Highlights, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'LSD1: biologic roles and therapeutic targeting'. Together they form a unique fingerprint.

Cite this